Industry Payments and Prescribing of Brand-Name Multiple Sclerosis Medications in Medicare | Synapse
April 10, 2026
Industry Payments and Prescribing of Brand-Name Multiple Sclerosis Medications in Medicare
Key Points
The study aims to investigate the relationship between industry payments to clinicians and the prescribing patterns of brand-name multiple sclerosis medications.
Analyzed payments made to clinicians from the industry.
Examined prescribing data for multiple sclerosis medications in Medicare.
Compared uptake rates of brand-name versus generic medications.
Industry payments were linked to reduced prescriptions of generic MS drugs.
Patients faced increased costs due to higher brand-name medication uptake.
The US health care system experienced elevated spending as a result.
Abstract
Payments to clinicians were associated with lower uptake of generic versions of 2 MS drugs, resulting in higher spending by patients and the US health care system.